% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gudenkauf:276415,
      author       = {L. M. Gudenkauf and M. N. Chavez and M. L. Maconi and C.
                      Geiss and A. Seyedroudbari and P. Thin and A. I. Hoogland
                      and K. Nguyen and V. Murthy and W. R. Armstrong and K.
                      Komrokji and L. B. Oswald and H. S. L. Jim and G. El-Haddad
                      and W. P. Fendler$^*$ and K. Herrmann$^*$ and D. Cella and
                      J. Czernin and M. S. Hofman and A. P. Dicker and J. Calais
                      and S. T. Tagawa and B. D. Gonzalez},
      title        = {{D}eveloping a {P}atient-{R}eported {O}utcome {M}easure for
                      {R}adionuclide {T}herapy for {P}rostate {C}ancer.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {6},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-01098},
      pages        = {869 - 872},
      year         = {2023},
      abstract     = {The field of radionuclide therapy (RNT) for prostate cancer
                      (PC) is growing rapidly, with recent Food and Drug
                      Administration approval of the first 177Lu-PSMA ligand. We
                      aimed to develop the first patient-reported outcome (PRO)
                      measure for PC patients receiving RNT. Methods: We
                      identified relevant symptoms and toxicities by reviewing
                      published trials and interviews with PC patients receiving
                      RNT (n = 29), caregivers (n = 14), and clinicians (n = 11).
                      Second, we selected items for measure inclusion. Third, we
                      refined the item list with input from experts in RNTs and
                      PROs. Fourth, we finalized the Functional Assessment of
                      Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient
                      input. Results: This multistep process yielded a brief
                      15-item measure deemed by key stakeholders to be relevant
                      and useful in the context of RNT for PC. Conclusion: The
                      FACT-RNT is a new standardized tool to monitor relevant
                      symptoms and toxicities among PC patients in RNT trials and
                      real-world settings.},
      keywords     = {Male / Humans / Prostatic Neoplasms: radiotherapy /
                      Prostatic Neoplasms: drug therapy / Radioisotopes:
                      therapeutic use / Patient Reported Outcome Measures /
                      genitourinary oncology (Other) / patient-reported outcomes
                      (Other) / prostate cancer (Other) / radionuclide therapy
                      (Other) / radiopharmaceuticals (Other) / Radioisotopes (NLM
                      Chemicals)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36635088},
      doi          = {10.2967/jnumed.122.264946},
      url          = {https://inrepo02.dkfz.de/record/276415},
}